The combination therapy of galectin-9 and oxaliplatin has the potential to induce antitumor immunity through polarization of tumor suppressive macrophages, mobilization of cytotoxic T lymphocytes, and down-regulation of regulatory T cells to achieve a significant therapeutic effect in PDAC treatment. This evidence concerns the gene LGALS9 and neoplasm.